サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1634148

糖尿病治療薬の世界市場 - 2025～2032年

Global Diabetes Drugs Market - 2025 - 2032

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
糖尿病治療薬の世界市場 - 2025～2032年
出版日: 2025年01月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の糖尿病治療薬市場は、2024年に781億1,000万米ドルに達し、2032年には1,417億3,000万米ドルに達すると予測され、予測期間2025年のCAGRは7.8%で成長します。

糖尿病は、膵臓でインスリンが十分に分泌されないか、分泌されたインスリンを体が有効に利用できない場合に生じる慢性疾患です。インスリンは血糖値の調整に不可欠なホルモンです。糖尿病がコントロールされないと、一般に血糖値の上昇と呼ばれる高血糖を引き起こします。高血糖は長期にわたると、さまざまな身体系に重大な障害を引き起こし、特に神経や血管に影響を及ぼします。

糖尿病治療薬は、糖尿病患者の血糖値を管理するために不可欠であり、心血管疾患、腎不全、神経損傷、視力障害などの重篤な合併症のリスクを軽減するのに役立ちます。薬剤の選択は、糖尿病のタイプ（1型または2型）、患者の全体的な健康状態、さまざまな治療に対する反応など、いくつかの要因に影響されます。

2022年の世界保健機関（WHO）のデータによると、18歳以上の成人の約14％が糖尿病とともに生活しており、1990年の7％から顕著に増加しています。驚くべきことに、糖尿病と診断された30歳以上の成人の半数以上（59％）が、2022年には糖尿病の治療を受けていませんでした。さらに、低・中所得国では糖尿病の治療率が特に低いです。

糖尿病が健康に与える影響は深刻で、2021年には160万人の死亡の直接の原因となり、その47％が70歳未満で発生しています。さらに、糖尿病は腎臓病による53万人の死亡の原因となり、心臓血管関連の死亡の約11%に関連しています。これらの要因が、世界の糖尿病治療薬市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

糖尿病有病率の上昇

糖尿病有病率の上昇が糖尿病治療薬世界市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予測されています。

肥満率とライフスタイルの変化による2型糖尿病患者の増加が、糖尿病治療薬の世界市場の成長を促進する主要因となっています。

世界の糖尿病疫学

国際糖尿病連合（IDF）が2021年に報告したデータによると、20～79歳の成人の10.5％が糖尿病患者であり、これは約5億3,000万人に相当します。この数字は2045年までに7億8,300万人に増加すると予測されており、成人の約8人に1人に相当し、有病率が46％増加することになります。これらすべての要因が、世界の糖尿病治療薬市場に需要をもたらしています。

さらに、主要企業の製品発売と承認、糖尿病管理の進歩が糖尿病治療薬市場の成長を促進します。例えば、2024年1月、Dong-A STは2型糖尿病の治療を目的とした新しい配合剤を発売し、これは糖尿病管理における重要な進歩です。この合剤（FDC）には3つの有効成分が配合されている：テネリグリプチン、ダパグリフロジン、メトホルミンの3つの有効成分が配合されています。この配合剤は、2型糖尿病患者、特にHbA1c値が高く、高血圧や心血管疾患などの合併症を有する患者の血糖コントロールを改善するように設計されています。

同様に2023年10月、ザイダスライフサイエンス社は、25mg、50mg、100mgの用量を有するZITUVIO（シタグリプチン）錠の新薬承認申請（NDA）が米国食品医薬品局（FDA）により承認されたと発表しました。ZITUVIOは、ジペプチジルペプチダーゼ-4（DPP-4）阻害薬に分類されるシタグリプチンを含有しています。本剤は、2型糖尿病と診断された成人患者を対象に、食事療法および運動療法と併用して血糖コントロールの改善を図ります。

また、グレンマーク社は2022年4月、DPP4阻害剤テネリグリプチンとチアゾリジンジオン（TZD）系薬剤ピオグリタゾンの新規合剤（FDC）を発売しました。ジータ・プラス・ピオの製品名で販売されているこのFDCは、テネリグリプチン20mgとピオグリタゾン15mgを含有し、1日1回服用します。このFDCは、成人におけるコントロール不能な2型糖尿病の治療薬として、インドで唯一入手可能なDPP4とグリタゾンの配合剤です。これらすべての要因が、世界の糖尿病治療薬市場に需要をもたらしています。

さらに、糖尿病治療の進歩に対する需要の高まりも、世界の糖尿病治療薬市場の拡大に寄与しています。

糖尿病治療薬の高コスト

糖尿病治療薬の高コストは、糖尿病治療薬の世界市場における大きな障壁となっており、多くの患者にとって重要な治療へのアクセスを制限しています。この問題に取り組むためには、政策立案者、ヘルスケアプロバイダー、製薬企業が協力し、購入しやすい価格を実現し、糖尿病患者全員が効果的な病態管理に必要な医薬品を入手できるようにする必要があります。

糖尿病治療薬の高額な費用は、保険未加入者や低所得者層に不釣り合いな影響を及ぼします。糖尿病患者の多くは、十分な健康保険に加入していなかったり、高額な自己負担があったりして、治療を受けることができません。米国糖尿病協会によると、インスリンへの支出は過去10年間で3倍に増加し、2012年の80億米ドルから2022年には223億米ドルになるといいます。したがって、上記の要因が世界の糖尿病治療薬市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病の罹患率の上昇
    • 抑制要因
      • 糖尿病治療薬の高コスト
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 薬剤クラス別

  • インスリン
    • 基礎インスリン
    • ボーラスインスリン
    • 従来のヒトインスリン
    • インスリンバイオシミラー
  • GLP-1受容体作動薬
    • エキセナチド
    • リキシセナチド
    • リラグルチド
    • デュラグルチド
    • セマグルチド
  • DPP-4阻害剤
    • シタグリプチン
    • サクサグリプチン
    • リナグリプチン
    • アログリプチン
  • SGLT2阻害剤
    • カナグリフロジン
    • ダパグリフロジン
    • エンパグリフロジン
    • エルツグリフロジン
  • ビグアナイド（メトホルミン）
  • チアゾリジンジオン
    • ピオグリタゾン
    • ロシグリタゾン
  • メグリチニド
    • レパグリニド
    • ナテグリニド
  • アルファグルコシダーゼ阻害剤
    • アカルボース
    • ミグリトール

第7章 糖尿病の種類別

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第8章 投与経路別

  • オーラル
  • 非経口

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Sanofi
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Novo Nordisk
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH.
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • AstraZeneca.
  • Bristol Myers Squibb
  • GSK plc

第13章 付録

目次
Product Code: PH8955

The global diabetes drugs market reached US$ 78.11 billion in 2024 and is expected to reach US$ 141.73 billion by 2032, growing at a CAGR of 7.8 % during the forecast period 2025-2032.

Diabetes is a chronic condition that arises when the pancreas either fails to produce sufficient insulin or when the body cannot effectively utilize the insulin it produces. Insulin is a hormone essential for regulating blood glucose levels. When diabetes is uncontrolled, it can lead to hyperglycemia, commonly referred to as elevated blood sugar levels. Over time, hyperglycemia can cause significant damage to various bodily systems, particularly affecting nerves and blood vessels.

Diabetes drugs are essential for managing blood glucose levels in individuals with diabetes, helping to mitigate the risk of serious complications such as cardiovascular disease, kidney failure, nerve damage, and vision problems. The choice of medication is influenced by several factors, including the type of diabetes (Type 1 or Type 2), the patient's overall health status, and their response to various treatments.

According to the World Health Organization (WHO) data in 2022, approximately 14% of adults aged 18 and older were living with diabetes, a notable increase from 7% in 1990. Alarmingly, more than half (59%) of adults aged 30 and over diagnosed with diabetes were not receiving medication for their condition in 2022. Furthermore, diabetes treatment coverage was particularly low in low- and middle-income countries.

The impact of diabetes on health is severe in 2021, it was directly responsible for 1.6 million deaths, with 47% of these fatalities occurring in individuals under the age of 70. Additionally, diabetes contributed to another 530,000 deaths due to kidney disease and was linked to approximately 11% of cardiovascular-related deaths. These factors have driven the global diabetes drugs market expansion.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The rising prevalence of diabetes is significantly driving the growth of the global diabetes drugs market and is expected to drive throughout the market forecast period.

The increase in Type 2 diabetes cases driven by obesity rates and lifestyle changes is a primary factor fueling the growth of the global diabetes drugs market.

Global Diabetes Epidemiology

According to the International Diabetes Federation (IDF) reported data in 2021, 10.5% of adults aged 20 to 79 were living with diabetes, which translates to approximately 530 million individuals. This figure is anticipated to rise to 783 million by 2045, equating to about 1 in 8 adults, marking a 46% increase in prevalence. All these factors demand the global diabetes drugs market.

Moreover, key player's product launches & approvals, and advancements in diabetes management drive this diabetes drugs market growth. For instance, in January 2024, Dong-A ST launched a new combination drug aimed at treating type 2 diabetes, which is a significant advancement in diabetes management. This fixed-dose combination (FDC) drug combines three active ingredients: Teneligliptin, Dapagliflozin, and Metformin. This combination is designed to improve glycemic control in patients with type 2 diabetes, particularly those with high HbA1c levels and other co-morbidities such as hypertension or cardiovascular issues.

Similarly, in October 2023, Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ZITUVIO (Sitagliptin) tablets, available in dosages of 25 mg, 50 mg, and 100 mg. ZITUVIO contains sitagliptin, which is classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is indicated to be used alongside diet and exercise to help improve glycemic control in adults diagnosed with type 2 diabetes mellitus.

Also, in April 2022, Glenmark Pharmaceuticals introduced a novel fixed-dose combination (FDC) of the DPP4 inhibitor Teneligliptin and the thiazolidinedione (TZD) Pioglitazone. This FDC, marketed under the brand name Zita Plus Pio, contains Teneligliptin 20 mg and Pioglitazone 15 mg, to be taken once daily. It is the only available DPP4 and glitazone combination in India for managing uncontrolled type 2 diabetes in adults. All these factors demand the global diabetes drugs market.

Moreover, the rising demand for advancements in diabetes treatment contributes to the global diabetes drugs market expansion.

High Cost of Diabetes Medications

The high cost of diabetes medications represents a major barrier in the global diabetes drugs market, restricting access to vital treatments for many patients. To tackle this issue, policymakers, healthcare providers, and pharmaceutical companies need to collaborate to enhance affordability and ensure that all individuals living with diabetes have access to the necessary medications for the effective management of their condition.

The high cost of diabetes medications disproportionately affects uninsured and low-income populations. Many individuals living with diabetes may not have adequate health insurance coverage or face high out-of-pocket expenses that make treatment unaffordable. According to the American Diabetes Association, spending on insulin has tripled over the past decade, rising from $8 billion in 2012 to $22.3 billion in 2022. Thus, the above factors could be limiting the global diabetes drugs market's potential growth.

Segment Analysis

The global diabetes drugs market is segmented based on Drug Class, Diabetes Type, Route of Administration, Distribution Channel, and region.

Drug Class:

The GLP-1 receptor agonists segment is expected to dominate the global diabetes drugs market share

The GLP-1 receptor agonists segment holds a major portion of the global diabetes drugs market share and is expected to continue to hold a significant portion of the global diabetes drugs market share during the forecast period.

Glucagon-like peptide-1 (GLP-1) analogues, commonly known as GLP-1 receptor agonists or incretin mimetics, are a category of medications that replicate the actions of the naturally occurring hormone GLP-1. This hormone is secreted by the intestines after food consumption and is essential for glucose regulation. It enhances insulin secretion, inhibits glucagon release, and promotes feelings of fullness. These medications are mainly utilized to treat type 2 diabetes and obesity, as they effectively lower blood sugar levels and assist in weight loss by reducing appetite and caloric intake. These factors have driven the global diabetes drugs market expansion.

Furthermore, key players' strategies such as partnerships & collaborations, and product launches & approvals would drive the diabetes drugs market growth. For instance, in November 2023, AstraZeneca announced its strategic approach to the cardiometabolic market, particularly focusing on treating obesity and its associated co-morbidities. This strategy involves combining the recently acquired GLP-1 receptor agonist therapy from Eccogene, known as ECC5004, with their existing cardiometabolic therapies, specifically the sodium-glucose co-transporter-2 (SGLT2) inhibitor Farxiga (dapagliflozin).

Also, in March 2022, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new 2.0 mg dose of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) analogue, for the treatment of adults with type 2 diabetes. This approval expands the available dosing options for Ozempic, which now includes 0.5 mg, 1.0 mg, and the newly approved 2.0 mg doses. These factors have solidified the segment's position in the global diabetes drugs market.

Geographical Analysis

North America is expected to hold a significant position in the global diabetes drugs market share

North America holds a substantial position in the global diabetes drugs market and is expected to hold most of the market share.

Diabetes Epidemiology in the U.S.

The rising incidence of type 2 diabetes is a primary driver of market growth in North America. According to the CDC, in 2021, approximately 38.4 million individuals of all ages, representing 11.6% of the U.S. population, were diagnosed with diabetes. Among adults aged 18 and older, this figure rose to 38.1 million, accounting for 14.7% of all U.S. adults.

Notably, 8.7 million adults in this age group met the laboratory criteria for diabetes but were either unaware of their condition or did not report it, which constitutes 3.4% of all U.S. adults and 22.8% of those with diabetes. The prevalence of diabetes among adults increases with age, reaching 29.2% for those aged 65 and older. Furthermore, rising obesity rates, technological advancements, government initiatives and support, and research and development drive this global diabetes drugs market growth.

Moreover, a major number of key player's presence, well-advanced healthcare infrastructure, and product launches & approvals would drive this global diabetes drugs market growth in this region. For instance, in June 2023, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) for use in children aged 10 and older with type 2 diabetes, as part of a treatment plan that includes diet and exercise. This marks the introduction of a new class of oral medications for pediatric type 2 diabetes management.

Also, in January 2023, TheracosBio announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. Brenzavvy is indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes. It is not recommended for individuals with type 1 diabetes mellitus or the treatment of diabetic ketoacidosis.

In addition, key players more focus on the treatment for type-2, and innovative launches help to drive this market growth. For instance, in August 2023, Dr. Reddy's Laboratories launched Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. This product is a generic equivalent of Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) tablets, which has received approval from the U.S. Food and Drug Administration (USFDA). Thus, the above factors are consolidating the region's position as a dominant force in the global diabetes drugs market.

Asia Pacific is growing at the fastest pace in the global diabetes drugs market share

Asia Pacific holds the fastest pace in the global diabetes drugs market and is expected to hold most of the market share.

The Asia-Pacific region is experiencing significant growth in the prevalence of diabetes, currently home to 60% of the global diabetic population. Notably, India and China account for approximately half of this figure. Other countries such as Indonesia, Thailand, and Japan are also witnessing an increase in diabetes cases.

Diabetes Epidemiology in Asia-Pacific

As per Abbott news in February 2022, India has the second-largest diabetes population globally, with recent studies indicating significant disruptions in healthcare for non-communicable diseases due to the pandemic. Up to 87% of individuals with diabetes have reduced their visits to healthcare providers, and less than half own a blood glucose monitoring device at home. For adults with type 2 diabetes who are on intensive insulin therapy, research has shown that using sensor-based devices for at least three months can lower average HbA1c levels from 8.9% to 8%.

According to the International Diabetes Federation (IDF) statistics from 2021, there are 90 million adults aged 20-79 living with diabetes in the South East Asia (SEA) region. Alarmingly, 46 million of these adults remain undiagnosed, and approximately 1 in 4 live births are affected by hyperglycemia during pregnancy. Similarly, in April 2024, a U.S. company introduced a diabetes educational program aimed at individuals in Singapore, reflecting a growing focus on diabetes management in the region. Projections by the IDF indicate that by 2045, the number of people living with diabetes could rise to 783 million globally.

Furthermore, key players in the region and product launches would drive this global diabetes drugs market growth. For instance, in October 2023, Glenmark Pharmaceuticals launched a triple-combination drug for the treatment of Type 2 diabetes, branded as Zita DM. This innovative medication is notable for being the first of its kind in India that combines three active ingredients into a single fixed-dose combination (FDC), aimed at improving glycemic control in adults with diabetes. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global diabetes drugs market.

Competitive Landscape

The major global players in the diabetes drugs market include Sanofi, Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim International GmbH., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, AstraZeneca., Bristol Myers Squibb, and GSK plc among others.

Key Developments

  • In April 2024, Sanofi India officially launched its new diabetes medication, Soliqua, following the approval from the Central Drugs Standard Control Organization (CDSCO) last year. This drug is specifically designed for adults with obesity and type 2 diabetes mellitus, aimed at improving glycemic control as an adjunct to diet and exercise for those who have not achieved adequate control with existing oral or injectable therapies.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global diabetes drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Diabetes Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Diabetes
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Diabetes Medications
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Drug Class

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 6.1.2. Market Attractiveness Index, By Drug Class
  • 6.2. Insulin*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Basal Insulin
    • 6.2.4. Bolus Insulin
    • 6.2.5. Traditional Human Insulin
    • 6.2.6. Insulin Biosimilars
  • 6.3. GLP-1 Receptor Agonists
    • 6.3.1. Exenatide
    • 6.3.2. Lixisenatide
    • 6.3.3. Liraglutide
    • 6.3.4. Dulaglutide
    • 6.3.5. Semaglutide
  • 6.4. DPP-4 Inhibitors
    • 6.4.1. Sitagliptin
    • 6.4.2. Saxagliptin
    • 6.4.3. Linagliptin
    • 6.4.4. Alogliptin
  • 6.5. SGLT2 Inhibitors
    • 6.5.1. Canagliflozin
    • 6.5.2. Dapagliflozin
    • 6.5.3. Empagliflozin
    • 6.5.4. Ertugliflozin
  • 6.6. Biguanides (Metformin)
  • 6.7. Thiazolidinediones
    • 6.7.1. Pioglitazone
    • 6.7.2. Rosiglitazone
  • 6.8. Meglitinides
    • 6.8.1. Repaglinide
    • 6.8.2. Nateglinide
  • 6.9. Alpha-glucosidase Inhibitors
    • 6.9.1. Acarbose
    • 6.9.2. Miglitol

7. By Diabetes Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
    • 7.1.2. Market Attractiveness Index, By Diabetes Type
  • 7.2. Type 1 Diabetes*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Type 2 Diabetes
  • 7.4. Gestational Diabetes

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Sanofi*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Novo Nordisk
  • 12.3. Eli Lilly and Company
  • 12.4. Boehringer Ingelheim International GmbH.
  • 12.5. Merck & Co., Inc.
  • 12.6. Takeda Pharmaceutical Company Limited
  • 12.7. Johnson & Johnson
  • 12.8. AstraZeneca.
  • 12.9. Bristol Myers Squibb
  • 12.10. GSK plc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us